

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 31	IFICDB, IFIPAT, and IFIUIDB enhanced with new custom IPC display formats
NEWS	3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	4	MAR 31	CA/CAPplus and CASREACT patent number format for U.S. applications updated
NEWS	5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	17	JUN 25	CA/CAPplus and USPAT databases updated with IPC reclassification data
NEWS	18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	22	JUL 28	CA/CAPplus patent coverage enhanced
NEWS	23	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	24	JUL 28	IFICDB, IFIPAT, and IFIUIDB reloaded with enhancements
NEWS	25	JUL 28	STN Viewer performance improved
NEWS	26	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:26:17 ON 07 AUG 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:26:26 ON 07 AUG 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 AUG 2008 HIGHEST RN 1039104-40-9

DICTIONARY FILE UPDATES: 6 AUG 2008 HIGHEST RN 1039104-40-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10538355.str



chain nodes :

12 13 14 15 17

```

ring nodes :
1  2  3  4  5  6  7  8  9  10  16
chain bonds :
1-12  2-13  3-14  7-15  8-16  10-17
ring bonds :
1-2  1-6  2-3  3-4  4-5  4-7  5-6  5-10  7-8  8-9  9-10
exact/norm bonds :
8-16  10-17
exact bonds :
1-12  2-13  3-14  7-15
normalized bonds :
1-2  1-6  2-3  3-4  4-5  4-7  5-6  5-10  7-8  8-9  9-10
isolated ring systems :
containing 1 :

```

```

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 09:26:41 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 124 TO ITERATE

100.0% PROCESSED 124 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1812 TO 3148

PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 09:26:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2549 TO ITERATE

100.0% PROCESSED 2549 ITERATIONS 68 ANSWERS
SEARCH TIME: 00.00.01

L3 68 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.36	178.57

FILE 'CAPLUS' ENTERED AT 09:26:50 ON 07 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Aug 2008 VOL 149 ISS 6
FILE LAST UPDATED: 6 Aug 2008 (20080806/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l3 full


L4 1 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:534201 CAPLUS
DOCUMENT NUMBER: 141:71530
TITLE: Preparation of [1,7]naphthyridines as PDE4 inhibitors
INVENTOR(S): Denholm, Alastair; Keller, Thomas Hugo; Mccarthy, Clive; Press, Neil John; Taylor, Roger John
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055013	A1	20040701	WO 2003-EP14263	20031215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2505405	A1	20040701	CA 2003-2505405	20031215
AU 2003293886	A1	20040709	AU 2003-293886	20031215
EP 1575950	A1	20050921	EP 2003-789283	20031215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017330	A	20051108	BR 2003-17330	20031215
CN 1726215	A	20060125	CN 2003-80106300	20031215
JP 2006511539	T	20060406	JP 2004-560419	20031215
EP 1777226	A1	20070425	EP 2007-100446	20031215
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR				
US 20060058338	A1	20060316	US 2005-538355	20050808
PRIORITY APPLN. INFO.:			GB 2002-29281	A 20021216
			EP 2003-789283	A3 20031215
			WO 2003-EP14263	W 20031215
OTHER SOURCE(S):	MARPAT 141:71530			
GI				



AB The title compds. [I; R1 = aryl having up to 10 carbon atoms; NR2R3 = heterocyclyl having up to 10 ring atoms and having 1-4 heteroatoms in the ring system; in free or salt form] which are useful for treating conditions mediated by of phosphodiesterase type 4 or the down-regulation or inhibition of TNF- α release, particularly obstructive or inflammatory airways diseases, were prepared E.g., a 3-step synthesis of


3-[6-(3-hydroxypyrrolidin-1-yl)-[1,7]naphthyridin-8-yl]benzonitrile, starting from 6-amino-8-bromo-1,7-naphthyridine and 3-cyanophenylboronic acid, which showed IC50 of 1 nM for inhibition of PDE4D, was given. Pharmaceutical compns. that contain compds. I and processes for preparing the compds. I are claimed.

IT 713145-28-9P 713145-30-3P 713145-47-2P
713145-56-3P 713145-62-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of [1,7]naphthyridines as PDE4 inhibitors)


RN 713145-28-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]-, ethyl ester (CA INDEX NAME)




RN 713145-30-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[8-(5-fluoro-2-methoxyphenyl)-1,7-naphthyridin-6-yl]-, ethyl ester (CA INDEX NAME)




RN 713145-47-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[8-[3-(methylthio)phenyl]-1,7-naphthyridin-6-yl]- (CA INDEX NAME)




RN 713145-56-3 CAPLUS

CN Acetic acid, 2-[[1-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]-4-piperidinyl]oxy]- (CA INDEX NAME)



RN 713145-62-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]- (CA INDEX NAME)



IT	713145-07-4P	713145-08-5P	713145-09-6P
	713145-10-9P	713145-11-0P	713145-12-1P
	713145-13-2P	713145-14-3P	713145-15-4P
	713145-16-5P	713145-17-6P	713145-18-7P
	713145-19-8P	713145-20-1P	713145-21-2P
	713145-22-3P	713145-23-4P	713145-24-5P
	713145-25-6P	713145-26-7P	713145-27-8P
	713145-29-0P	713145-31-4P	713145-32-5P
	713145-33-6P	713145-34-7P	713145-35-8P
	713145-36-9P	713145-37-0P	713145-38-1P
	713145-39-2P	713145-40-5P	713145-41-6P
	713145-42-7P	713145-43-8P	713145-44-9P
	713145-45-0P	713145-46-1P	713145-48-3P
	713145-49-4P	713145-50-7P	713145-63-2P

713145-64-3P 713145-65-4P 713145-66-5P


713145-67-6P 713145-68-7P 713145-69-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of [1,7]naphthyridines as PDE4 inhibitors)


RN 713145-07-4 CAPLUS

CN Benzonitrile, 3-[6-(3-hydroxy-1-pyrrolidinyl)-1,7-naphthyridin-8-yl]- (CA
INDEX NAME)



RN 713145-08-5 CAPLUS


CN 1-Piperazinepropanenitrile, 4-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 713145-09-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]-,
lithium salt (1:1) (CA INDEX NAME)




● Li

RN 713145-10-9 CAPLUS
 CN Benzonitrile, 3-[6-(1-piperazinyl)-1,7-naphthyridin-8-yl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 713145-11-0 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]- (CA INDEX NAME)




RN 713145-12-1 CAPLUS
 CN Benzonitrile, 3-[6-(4-hydroxy-1-piperidinyl)-1,7-naphthyridin-8-yl]- (CA INDEX NAME)



RN 713145-13-2 CAPLUS
 CN Benzonitrile, 3-[6-[4-(hydroxymethyl)-1-piperidinyl]-1,7-naphthyridin-8-yl]- (CA INDEX NAME)




RN 713145-14-3 CAPLUS
 CN Benzonitrile, 3-[6-[4-(2-hydroxyethyl)-1-piperidinyl]-1,7-naphthyridin-8-yl]- (CA INDEX NAME)




RN 713145-15-4 CAPLUS
 CN Benzonitrile, 3-[6-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-1,7-naphthyridin-8-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 713145-16-5 CAPLUS

CN Benzonitrile, 3-[6-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-1,7-naphthyridin-8-yl]- (CA INDEX NAME)




RN 713145-17-6 CAPLUS

CN 3-Piperidinecarboxamide, 1-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]- (CA INDEX NAME)



RN 713145-18-7 CAPLUS


CN Benzonitrile, 3-[6-(4-morpholinyl)-1,7-naphthyridin-8-yl]- (CA INDEX NAME)



RN 713145-19-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 713145-20-1 CAPLUS


CN L-Proline, 1-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 713145-21-2 CAPLUS

CN Benzonitrile, 3-[6-(4-methyl-1-piperazinyl)-1,7-naphthyridin-8-yl]- (CA INDEX NAME)




RN 713145-22-3 CAPLUS
 CN 1-Piperazineacetic acid, 4-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]-,
 lithium salt (1:1) (CA INDEX NAME)




● Li


RN 713145-23-4 CAPLUS
 CN 1-Piperazineacetic acid, 4-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]-,
 ethyl ester (CA INDEX NAME)



RN 713145-24-5 CAPLUS
 CN Benzonitrile, 3-[6-[4-(methylsulfonyl)-1-piperazinyl]-1,7-naphthyridin-8-yl]-
 (CA INDEX NAME)




RN 713145-25-6 CAPLUS
 CN Benzonitrile, 3-[6-(3,5-dimethyl-1-piperazinyl)-1,7-naphthyridin-8-yl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 713145-26-7 CAPLUS
 CN Benzonitrile, 3-[6-(4-ethyl-1-piperazinyl)-1,7-naphthyridin-8-yl]- (CA INDEX NAME)



RN 713145-27-8 CAPLUS
 CN 3-Azetidinecarboxylic acid, 1-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]- (CA INDEX NAME)




RN 713145-29-0 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 713145-31-4 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[8-(5-fluoro-2-methoxyphenyl)-1,7-naphthyridin-6-yl]-, potassium salt (1:1) (CA INDEX NAME)




● K

RN 713145-32-5 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[8-(3-chlorophenyl)-1,7-naphthyridin-6-yl]-, ethyl ester (CA INDEX NAME)




RN 713145-33-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[8-(5-chloro-2-methoxyphenyl)-1,7-naphthyridin-6-yl]-, ethyl ester (CA INDEX NAME)




RN 713145-34-7 CAPLUS

CN Benzoic acid, 3-[6-(4-morpholinyl)-1,7-naphthyridin-8-yl]- (CA INDEX NAME)



RN 713145-35-8 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[8-(3-chlorophenyl)-1,7-naphthyridin-6-yl]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 713145-36-9 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[8-(3-chlorophenyl)-1,7-naphthyridin-6-yl]-, ethyl ester (CA INDEX NAME)




RN 713145-37-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[8-(5-chloro-2-methoxyphenyl)-1,7-naphthyridin-6-yl]-, ethyl ester (CA INDEX NAME)



RN 713145-38-1 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[8-(5-chloro-2-methoxyphenyl)-1,7-naphthyridin-6-yl]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 713145-39-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[8-(3-methoxyphenyl)-1,7-naphthyridin-6-yl]-
(CA INDEX NAME)




RN 713145-40-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[8-(3,5-difluorophenyl)-1,7-naphthyridin-6-yl]-
(CA INDEX NAME)




RN 713145-41-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[8-(3-methylphenyl)-1,7-naphthyridin-6-yl]-
(CA INDEX NAME)




RN 713145-42-7 CAPLUS
 CN Acetic acid, 2-[[1-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]-4-piperidinyl]oxy]-, potassium salt (1:1) (CA INDEX NAME)




● K

RN 713145-43-8 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[8-(1,3-benzodioxol-5-yl)-1,7-naphthyridin-6-yl]- (CA INDEX NAME)




RN 713145-44-9 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[8-[3-(trifluoromethoxy)phenyl]-1,7-naphthyridin-6-yl]- (CA INDEX NAME)




RN 713145-45-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[8-(3-chloro-4-fluorophenyl)-1,7-naphthyridin-6-yl]- (CA INDEX NAME)



RN 713145-46-1 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]-4-methyl-, potassium salt (1:1) (CA INDEX NAME)




● K

RN 713145-48-3 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[8-[3-(methylsulfinyl)phenyl]-1,7-naphthyridin-6-yl]- (CA INDEX NAME)



RN 713145-49-4 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-(8-phenyl-1,7-naphthyridin-6-yl)- (CA INDEX NAME)




RN 713145-50-7 CAPLUS
 CN 4-Piperidineacetic acid, 1-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]-, potassium salt (1:1) (CA INDEX NAME)




● K


RN 713145-63-2 CAPLUS
 CN 1-Piperazinepropanenitrile, 4-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]- (CA INDEX NAME)




RN 713145-64-3 CAPLUS
 CN Benzonitrile, 3-[6-(1-piperazinyl)-1,7-naphthyridin-8-yl]- (CA INDEX NAME)



RN 713145-65-4 CAPLUS
 CN 1-Piperazineacetic acid, 4-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]- (CA INDEX NAME)




RN 713145-66-5 CAPLUS
 CN Benzonitrile, 3-[6-(3,5-dimethyl-1-piperazinyl)-1,7-naphthyridin-8-yl]- (CA INDEX NAME)




RN 713145-67-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[8-(3-chlorophenyl)-1,7-naphthyridin-6-yl]-
(CA INDEX NAME)




RN 713145-68-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[8-(5-chloro-2-methoxyphenyl)-1,7-naphthyridin-6-yl]-
(CA INDEX NAME)




RN 713145-69-8 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]-4-methyl-
(CA INDEX NAME)




IT 713145-51-8P 713145-52-9P 713145-55-2P
 713145-57-4P 713145-58-5P 713145-59-6P
 713145-60-9P 713145-61-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of [1,7]naphthyridines as PDE4 inhibitors)
 RN 713145-51-8 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]-,
 ethyl ester (CA INDEX NAME)



RN 713145-52-9 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 713145-55-2 CAPLUS
 CN Acetic acid, 2-[[1-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]-4-
 piperidinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 713145-57-4 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]-4-methyl-, ethyl ester (CA INDEX NAME)




RN 713145-58-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[8-[3-(methylthio)phenyl]-1,7-naphthyridin-6-yl]-, ethyl ester (CA INDEX NAME)




RN 713145-59-6 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-, 1-[8-[3-(methylthio)phenyl]-1,7-naphthyridin-6-yl]-4-piperidinyl ester (CA INDEX NAME)




RN 713145-60-9 CAPLUS

CN 4-Piperidinamine, 1-[8-[3-(methylthio)phenyl]-1,7-naphthyridin-6-yl]- (CA INDEX NAME)



RN 713145-61-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[8-(3-cyanophenyl)-1,7-naphthyridin-6-yl]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.93

184.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.80

-0.80

STN INTERNATIONAL LOGOFF AT 09:27:14 ON 07 AUG 2008